Business Description
Altimmune Inc
NAICS : 325412
SIC : 2834
ISIN : US02155H2004
Compare
Compare
Traded in other countries / regions
ALT.USA0A4C.UK3G0.GermanyALT1.Mexico IPO Date
2021-02-09Description
Altimmune Inc is engaged in developing treatments for obesity and liver diseases. The Company's pipeline includes next-generation peptide therapeutics for obesity and non-alcoholic steatohepatitis (NASH) (for both, pemvidutide, formerly known as ALT-801), and for chronic hepatitis B (HepTcell). The Company is managed and operates as a single business focused on the research and development of treatments for various diseases and disorders, and vaccines.
Financial Strength
6/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Cash-To-Debt | 88.57 | |||||
| Equity-to-Asset | 0.88 | |||||
| Debt-to-Equity | 0.01 | |||||
| Debt-to-EBITDA | -0.02 | |||||
| Piotroski F-Score | 2/9 | |||||
| Altman Z-Score | 8.76 | |||||
| WACC vs ROIC | ||||||
Growth Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 3-Year Revenue Growth Rate | -70.7 | |||||
| 3-Year EBITDA Growth Rate | 7.8 | |||||
| 3-Year EPS without NRI Growth Rate | 9.3 | |||||
| 3-Year FCF Growth Rate | -1.8 | |||||
| 3-Year Book Growth Rate | -23.3 | |||||
| Future 3-5Y EPS without NRI Growth Rate | -3.74 |
Momentum Rank
9/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 5-Day RSI | 0.62 | |||||
| 9-Day RSI | 15.1 | |||||
| 14-Day RSI | 36.57 | |||||
| 6-1 Month Momentum % | -43.19 | |||||
| 12-1 Month Momentum % | 149.48 |
Liquidity Ratio
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Current Ratio | 11.3 | |||||
| Quick Ratio | 11.3 | |||||
| Cash Ratio | 10.88 | |||||
| Days Sales Outstanding | 509.39 |
Dividend & Buy Back
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 3-Year Average Share Buyback Ratio | -23.9 | |||||
| Shareholder Yield % | -15.37 |
Profitability Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Operating Margin % | -23785.58 | |||||
| Net Margin % | -24778.97 | |||||
| FCF Margin % | -17560.37 | |||||
| ROE % | -60.49 | |||||
| ROA % | -54.95 | |||||
| ROIC % | -1429.29 | |||||
| ROC (Joel Greenblatt) % | -15235.04 | |||||
| ROCE % | -58.88 |
GF Value Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| PS Ratio | 840 | |||||
| PB Ratio | 3.13 | |||||
| Price-to-Tangible-Book | 3.13 | |||||
| EV-to-EBIT | -3.1 | |||||
| EV-to-EBITDA | -3.17 | |||||
| EV-to-Forward-EBITDA | -3.07 | |||||
| EV-to-Revenue | 769.07 | |||||
| EV-to-Forward-Revenue | 11.7 | |||||
| EV-to-FCF | -4.4 | |||||
| Price-to-Net-Current-Asset-Value | 3.17 | |||||
| Price-to-Net-Cash | 3.31 | |||||
| Earnings Yield (Greenblatt) % | -32.26 | |||||
| FCF Yield % | -14.97 |
Historical Operating Revenue by Business Segment
Historical Operating Revenue by Geographic Region
Guru Trades
See DetailsInsider Trades
See DetailsPeter Lynch Chart
Performance
Dividend
Log
Bar
Annualized Return % Â
Total Annual Return % Â
Altimmune Inc Executives
DetailsAnalyst Estimate
Key Statistics
| Name | Value | ||
|---|---|---|---|
| Revenue (TTM) (Mil MXN) | 7.076 | ||
| EPS (TTM) (MXN) | -28.448 | ||
| Beta | 0.43 | ||
| Volatility % | 302.47 | ||
| 14-Day RSI | 36.57 | ||
| 14-Day ATR (MXN) | 0.048572 | ||
| 20-Day SMA (MXN) | 120.2 | ||
| 12-1 Month Momentum % | 149.48 | ||
| 52-Week Range (MXN) | 48.1 - 246 | ||
| Shares Outstanding (Mil) | 71.07 |
Piotroski F-Score Details
Year:
| Component | Result | ||
|---|---|---|---|
| Piotroski F-Score | 2 | ||
| Positive ROA | |||
| Positive CFROA | |||
| Higher ROA yoy | |||
| CFROA > ROA | |||
| Lower Leverage yoy | |||
| Higher Current Ratio yoy | |||
| Less Shares Outstanding yoy | |||
| Higher Gross Margin yoy | |||
| Higher Asset Turnover yoy |
Altimmune Inc Filings
| Filing Date | Document Date | Form | ||
|---|---|---|---|---|
| No Filing Data | ||||
Altimmune Inc Stock Events
| Event | Date | Price(MXN) | ||
|---|---|---|---|---|
| No Event Data | ||||
Altimmune Inc Frequently Asked Questions
What is Altimmune Inc(MEX:ALT1)'s stock price today?
The current price of MEX:ALT1 is MXN133.77. The 52 week high of MEX:ALT1 is MXN246.00 and 52 week low is MXN48.10.
When is next earnings date of Altimmune Inc(MEX:ALT1)?
The next earnings date of Altimmune Inc(MEX:ALT1) is 2024-11-07 Est..
Does Altimmune Inc(MEX:ALT1) pay dividends? If so, how much?
Altimmune Inc(MEX:ALT1) does not pay dividend.
Press Release
| Subject | Date | |||
|---|---|---|---|---|
| No Press Release | ||||
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers